Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

665 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM. Abramson JS, et al. Among authors: feldman t. Ann Oncol. 2014 Nov;25(11):2211-2217. doi: 10.1093/annonc/mdu443. Epub 2014 Sep 5. Ann Oncol. 2014. PMID: 25193992 Free PMC article.
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez A, Wang M, Weaver P, Hartig K, Kwak LW, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Romaguera JE, et al. Among authors: feldman t. Br J Haematol. 2010 Oct;151(1):47-53. doi: 10.1111/j.1365-2141.2010.08315.x. Epub 2010 Aug 5. Br J Haematol. 2010. PMID: 20735402 Free article. Clinical Trial.
Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD.
Mato AR, Svoboda J, Feldman T, Zielonka T, Agress H, Panush D, Miller M, Toth P, Lizotte PM, Nasta S, Goldberg S, Chong E, Schuster S, Pecora AL, Goy A. Mato AR, et al. Among authors: feldman t. Cancer. 2012 Jul 15;118(14):3565-70. doi: 10.1002/cncr.26731. Epub 2011 Dec 16. Cancer. 2012. PMID: 22180256 Free article.
Liquid tumors in the elderly.
Mato A, Feldman T, Richter J, Siegel DS, Goy A. Mato A, et al. Among authors: feldman t. Clin Geriatr Med. 2012 Feb;28(1):115-52. doi: 10.1016/j.cger.2011.12.002. Clin Geriatr Med. 2012. PMID: 22326039 No abstract available.
Targeting indolent non-Hodgkin lymphoma.
Leslie LA, Skarbnik AP, Bejot C, Stives S, Feldman TA, Goy AH. Leslie LA, et al. Expert Rev Hematol. 2017 Apr;10(4):299-313. doi: 10.1080/17474086.2017.1303374. Epub 2017 Mar 15. Expert Rev Hematol. 2017. PMID: 28277849 Review.
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Horwitz S, O'Connor OA, Pro B, Trümper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Menne T, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Zinzani PL, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Illidge T. Horwitz S, et al. Among authors: feldman t. Ann Oncol. 2022 Mar;33(3):288-298. doi: 10.1016/j.annonc.2021.12.002. Epub 2021 Dec 16. Ann Oncol. 2022. PMID: 34921960 Free PMC article. Clinical Trial.
665 results